基于模型与患者个体化剂量学的18F-DCFPyL(一种PSMA靶向PET显像剂)联合剂量学研究
研究对9例转移性前列腺癌患者静脉注射321±8 MBq的18F-DCFPyL后行系列PET/CT显像,采用OLINDA/EXM软件及基于理想化解剖联合患者个体化体积的蒙特卡罗模型计算主要器官吸收剂量,包括泪腺、唾液腺等既往缺乏模型的器官,并得出18F-DCFPyL的平均有效剂量为0.017±0.002 mSv/MBq。
要点
- 9例转移性前列腺癌患者行18F-DCFPyL PET/CT系列显像,给药活度为321±8 MBq。
- 单位 administered activity 下平均吸收剂量最高为泪腺,其次为下颌下腺、肾脏、膀胱壁和腮腺。
- 18F-DCFPyL的平均有效剂量为0.017±0.002 mSv/MBq。
核心结论
- 在9例转移性前列腺癌患者中获得了18F-DCFPyL的剂量学结果,所采用的泪腺和唾液腺新模型针对的是既往缺乏模型、且对治疗和诊断可能具有剂量限制性摄取的两个器官。
研究设计与样本
- 9例转移性前列腺癌患者静脉注射321±8 MBq(8.7±0.2 mCi)的18F-DCFPyL后,于约1、12、35和70分钟行系列PET/CT显像,并于约120分钟行最终PET/CT显像。
- 计算时间积分活度系数并作为OLINDA/EXM软件输入,以获得大多数主要器官的剂量估计。
- 眼晶状体和泪腺的吸收剂量采用基于理想化解剖联合PET/CT扫描所得患者个体化体积和活度的蒙特卡罗模型计算。
- 腮腺和下颌下腺两个主要唾液腺的剂量采用基于CT的患者个体化腺体体积的蒙特卡罗模型计算。
主要发现
- 每单位 administered activity 18F的最高平均吸收剂量见于泪腺,其次为下颌下腺、肾脏、膀胱壁和腮腺。
- 泪腺至眼晶状体的S值为0.42 mGy/MBq h,泪膜至眼晶状体的S值为1.78 mGy/MBq h,泪腺自身剂量的S值为574.10 mGy/MBq h。
- 唾液腺的平均S值:腮腺自身剂量为3.58 mGy/MBq h,下颌下腺自身剂量为6.78 mGy/MBq h。
- 18F-DCFPyL的平均有效剂量为0.017±0.002 mSv/MBq。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate-specific membrane antigen (PSMA), a type-II integral membrane protein highly expressed in prostate cancer, has been extensively used as a target for imaging and therapy. Among the available PET radiotracers, the low molecular weight agents that bind to PSMA are proving particularly effective. We present the dosimetry results for 18F-DCFPyL in nine patients with metastatic prostate cancer. METHODS: Nine patients were imaged using sequential PET/CT scans at approximately 1, 12, 35 and 70 min, and a final PET/CT scan at approximately 120 min after intravenous administration of 321 ± 8 MBq (8.7 ± 0.2 mCi) of18F-DCFPyL. Time-integrated-activity coefficients were calculated and used as input in OLINDA/EXM software to obtain dose estimates for the majority of the major organs. The absorbed doses (AD) to the eye lens and lacrimal glands were calculated using Monte-Carlo models based on idealized anatomy combined with patient-specific volumes and activity from the PET/CT scans. Monte-Carlo based models were also developed for calculation of the dose to two major salivary glands (parotid and submandibular) using CT-based patient-specific gland volumes. RESULTS: The highest calculated mean AD per unit administered activity of 18F was found in the lacrimal glands, followed by the submandibular glands, kidneys, urinary bladder wall, and parotid glands. The S-values for the lacrimal glands to the eye lens (0.42 mGy/MBq h), the tear film to the eye lens (1.78 mGy/MBq h) and the lacrimal gland self-dose (574.10 mGy/MBq h) were calculated. Average S-values for the salivary glands were 3.58 mGy/MBq h for the parotid self-dose and 6.78 mGy/MBq h for the submandibular self-dose. The resultant mean effective dose of 18F-DCFPyL was 0.017 ± 0.002 mSv/MBq. CONCLUSIONS: 18F-DCFPyL dosimetry in nine patients was obtained using novel models for the lacrimal and salivary glands, two organs with potentially dose-limiting uptake for therapy and diagnosis which lacked pre-existing models.
引用
- Plyku D, Mena E, Rowe SP, et al. Combined model-based and patient-specific dosimetry for 18F-DCFPyL, a PSMA-targeted PET agent. Eur J Nucl Med Mol Imaging. 2018. PMID: 29460025. doi:10.1007/s00259-018-3939-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。